About Kringle Pharma
Kringle Pharma is a publicly listed company based in Japan founded in 2001. Developer of recombinant protein drugs for neuro, renal and oncology disorders. Kringle Pharma has raised $32.06 million across 4 funding rounds from investors including Resona Group, Ogaki Kyoritsu Bank and Toho Bank. The company has 15 employees. Its focus areas include Diversified Pharmaceuticals.
Company details
Kringle Pharma, a spin-off from the Osaka University, is developing recombinant protein drugs for treating neuro, renal and oncology disorders. The company has developed NK4 (intramolecular fragment) with antagonist activity towards hepatocyte growth factor (HGF) which has a role in the regeneration and repair of various tissues and organs. The company developed and has cleared phase I trials of recombinant human HGF (KP-100IT) against ALS, along with the phase III trials for acute spinal cord injury and US phase 1 trial for acute kidney injury have been completed.
- Headquarters Ibaraki, Japan
- Employees 15
- Stage Public
- SectorsHealthcare
- Website category Health · Biotechnology and Pharmaceuticals
- Email••••••••
- Website kringle-pharma.com
- Legal Name Kringle Pharma, Inc.
- Annual Revenue$487.99 K (USD)-9.77as on Sep 30, 2025
- Net Profit-$6.19 M (USD)-21.13as on Sep 30, 2025
- EBITDA-$6.15 M (USD)-11.2as on Sep 30, 2025
- Total Equity Funding$32.06M (USD)
in 4 rounds
- Latest Funding Round$15.52M (USD), Series B
Apr 2020
- InvestorsResona Group
& 17 more
- Employee Count15
Funding Insights of Kringle Pharma
Kringle Pharma has successfully raised a total of $32.06M across 4 strategic funding rounds. The most recent funding activity was a Series B round of $15.52 million completed in April 2020. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding $32.06M
- Total Rounds 4
- Last Round Series B — $15.52M
- First Round $9.58M
(Dec 2007)
- Investors Count 18
All 4 funding rounds of Kringle Pharma with amounts and investors; the two latest post-money valuations are shown, the rest are part of the premium plan.
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Apr 2020 | $15.52M | Series B | – | Miraca Holdings, Nanto Bank | |
| Dec 2016 | $5.4M | Series A | – | DBJ Capital, Keio Innovation Initiative | |
| Mar 2008 | $1.56M | Series A | – | Nissay Capital | |
| Dec 2007 | $9.58M | Series A | – | Nissay Capital |
18 investors in total: 18 institutional.
Investors in Kringle Pharma
Kringle Pharma has secured backing from 18 investors, including institutional and venture fund investors. Prominent investors backing the company include Resona Group, Ogaki Kyoritsu Bank and Toho Bank.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
| ouvc.co.jp | ||||
| yitucapital.com | ||||
Venture capital investments are provided to innovative startups by DBJ Capital. | dbj-cap.jp | Japan | ||
Stage-agnostic investments in Japanese tech and life sciences are made. | 2015 | keio-innovation.co.jp | Tokyo, Japan | |
| g-cp.jp | ||||
Venture capital firm investing in biotech, adtech sectors | nissay-cap.co.jp | Chiyoda City, Japan | ||
VC firm investing in Japan and the US | nvcc.co.jp | Chiyoda City, Japan | ||
Outsourced clinical testing and health IT consulting services are provided. | 1950 | miraca.com | Shinjuku City, Japan | |
Commercial bank offering diversified financial services | 1934 | nantobank.co.jp | Nara, Japan | |
Commercial banking services including deposits and lending are provided. | 1896 | okb.co.jp | Ogaki, Japan |
Investor details for Kringle Pharma
The complete investor list, round-by-round participation and investor portfolios require an active premium plan.
- Complete investor list
- Round participation
- Investor portfolios
- Co-investor network
Verified entity values are shown only after access is granted.
IPO & Listings of Kringle Pharma
Kringle Pharma is a publicly listed company on the TSE with ticker symbol 4884 in Japan, operating in the Health technology sector. As a publicly traded entity, the company provides investors with opportunities to participate in its growth story through equity ownership. The listing enables access to capital markets, enhances corporate visibility, and provides liquidity for shareholders while maintaining transparency through regulatory compliance and regular financial disclosures.
- IPO date28 Dec 2020
- Listed onTSE: 4884
- Listed entityKringle Pharma, Inc.
- Exchange sectorHealth technology
- ISINJP3270790003
- Share price644.00 JPY (-7.47% on the day) · 2026-10-14
- Market capitalisation5,980,839,798.00 JPY
- EPS (diluted, trailing year)-110.73 JPY
- Volume (last session)607,300
Financials of Kringle Pharma
| Year | Revenue | Net income | EBITDA |
|---|---|---|---|
| 2025 | 72.2M JPY | -916.2M JPY | -909.5M JPY |
| 2024 | 80.0M JPY | -756.5M JPY | -817.9M JPY |
| 2023 | 69.2M JPY | -854.1M JPY | -888.8M JPY |
| 2022 | 391.8M JPY | -331.8M JPY | -426.2M JPY |
| 2021 | 289.8M JPY | -301.2M JPY | -357.9M JPY |
Detailed financial statements for Kringle Pharma
Statement rows, ratios, five-year trends and downloadable financials of the group companies require an active premium plan.
- Statement rows
- Financial ratios
- Five-year trends
- Downloads
Verified entity values are shown only after access is granted.
Timeline of Kringle Pharma
4 dated milestones of Kringle Pharma across 19 years, from founding to its latest funding, stage changes and deals.
- Founded Kringle Pharma is founded.
- Funding First funding round of $9.6M.
- Funding Latest funding round, Series B, of $15.5M.
- IPO Lists on the stock exchange (IPO).
Web traffic of Kringle Pharma
The website of Kringle Pharma (kringle-pharma.com) receives about 2.5K visits a month and ranks #2,077,026 among all websites worldwide, #2,831 in Biotechnology and Pharmaceuticals.
- Monthly visits2.5K
▼ 65.8% vs previous month
- Unique visitors2.9K
per month
- Global rank#2,077,026
among all websites
- Category rank#2,831
Health · Biotechnology and Pharmaceuticals
- Bounce rate31%
- Pages per visit4.1
- Average visit2 min 40 sec
- DevicesDesktop 26% · Mobile 74%
Websites whose visitors overlap most with Kringle Pharma. Affinity shows how closely the audiences match.
| Website | Domain | Audience affinity | Monthly visits | Global rank | Profile |
|---|---|---|---|---|---|
| mbl.co.jp | 100% | 38.2K | #751,970 | View details | |
koe-memai-futako.com | koe-memai-futako.com | 30% | #5,207,845 | – |
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Related news about Kringle Pharma
Complete news archive for Kringle Pharma
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Kringle Pharma
Kringle Pharma was founded in 2001 and raised its 1st funding round 6 years after it was founded.
Kringle Pharma is headquartered in Japan. It is registered at Ibaraki, Japan.
Kringle Pharma is a funded company, having raised a total of $32.06M across 4 funding rounds to date. The company's 1st funding round was a Series A of $9.58M, raised on Dec 2007.
Kringle Pharma has 15 employees.
Annual revenue of Kringle Pharma is $487.99K as on Sep 30, 2025.
Kringle Pharma, a spin-off from the Osaka University, is developing recombinant protein drugs for treating neuro, renal and oncology disorders. The company has developed NK4 (intramolecular fragment) with antagonist activity towards hepatocyte growth factor (HGF) which has a role in the regeneration and repair of various tissues and organs. The company developed and has cleared phase I trials of recombinant human HGF (KP-100IT) against ALS, along with the phase III trials for acute spinal cord injury and US phase 1 trial for acute kidney injury have been completed.
Yes, Kringle Pharma is publicly traded on TSE under the ticker symbol 4884.
Kringle Pharma has 18 investors. Key investors include Resona Group, Ogaki Kyoritsu Bank, Toho Bank, ReproCELL, and Cyberdyne.